Acella Recalls NP Thyroid 15 Tablets Due to Subpotent Levothyroxine Levels
Acella Pharmaceuticals is recalling NP Thyroid 15 tablets because FDA analysis found the levothyroxine content was less than labeled.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The agency classification is FDA Class I, which per the rubric mandates a minimum score of 4 (Severe).
Plain-English summary
Acella Pharmaceuticals, LLC is recalling 9,816 bottles of NP Thyroid 15 (Levothyroxine, Liothyronine) tablets. The affected product is identified by Lot # M328F19-3 with an expiration date of 11/2020. The product was distributed nationwide within the United States.
The recall was initiated because FDA analysis determined that the levothyroxine (T4) portion of the product was subpotent, meaning it contained less of the active ingredient than stated on the label. This discrepancy may result in patients not receiving the intended therapeutic effect of the medication.
Patients and consumers who have this specific lot of NP Thyroid 15 should stop using the product and contact their healthcare provider or pharmacist for guidance on alternative treatment options. The recall is limited to the specific lot number and expiration date listed above.
The recalled product
- Product
- NP THYROID 15 (LEVOTHYROXINE, LIOTHYRONINE)
- Brand
- NP THYROID 15
- Manufacturer
- Acella Pharmaceuticals, LLC
- Category
- Drug — Prescription Medication
- Hazard
- Affected units
- 9,816
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- Lot #: M328F19-3 Exp. 11/2020
UPCs (4)
- 0342192329102
- 0342192330108
- 0342192327016
- 0342192328013
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 2 recalled by Acella Pharmaceuticals, LLC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same brand · NP THYROID 15
- SevereAcella Recalls Subpotent NP Thyroid 15 Tablets Nationwide
FDA (Drugs) · 2021-06-02
- CriticalAcella Recalls Subpotent NP Thyroid 15 Tablets Nationwide
FDA (Drugs) · 2021-06-02
- CriticalAcella Recalls Subpotent NP Thyroid 15 Prescription Tablets
FDA (Drugs) · 2021-06-02
- CriticalAcella Pharmaceuticals Recalls Subpotent NP Thyroid 15 Prescription Tablets
FDA (Drugs) · 2021-06-02
- CriticalAcella Recalls Subpotent NP Thyroid 15 Tablets Nationwide
FDA (Drugs) · 2021-06-02
Same manufacturer · Acella Pharmaceuticals, LLC
See all →- SevereNaproxen Oral Suspension Recalled for Lead and Lithium Contamination
FDA (Drugs) · 2026-05-13
- ModerateDoxycycline hyclate tablets recalled after stability testing failed dissolution specifications
FDA (Drugs) · 2025-10-15
- ModeratePrescription skin cleanser recalled nationwide due to subpotency
FDA (Drugs) · 2024-05-15
- ModerateAcella Recalls Sodium Sulfacetamide Cleansing Pads for Subpotency
FDA (Drugs) · 2022-12-07
- LowPhenytoin Sodium Injection Recalled for Missing Barcode on Vial Label
FDA (Drugs) · 2022-11-30
Same hazard · subpotent drug
See all →- ModerateAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- HighAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- HighAccord Healthcare Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- HighAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02